Canaccord analyst Edward Nash initiated coverage of Sagimet Biosciences (SGMT) with a Buy rating and $28 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Largest borrow rate increases among liquid names
- 3 Best Stocks to Buy Now, 6/23/2025, According to Top Analysts
- Buy Rating for Sagimet Biosciences Driven by Promising Clinical Data and Market Potential of Denifanstat
- Sagimet Biosciences Elects New Directors at Annual Meeting
- Sagimet Biosciences to host KOL event on denifanstat results